Management of Elevated Creatine Kinase Levels with Medications

Statins and CK Elevation

The American College of Cardiology recommends that statins should be discontinued immediately if CK is greater than 10 times the upper limit of normal (ULN) with muscle symptoms, or if muscle symptoms are severe with any CK elevation 1
Statins are the primary medications that should be stopped or adjusted with elevated CK levels, as they can cause myopathy, myositis, and rhabdomyolysis 1

Asymptomatic patients with CK >10x ULN should have strong consideration given to stopping statin therapy, according to the American College of Cardiology 1
Patients with muscle symptoms and CK >10x ULN should discontinue statin therapy immediately, as recommended by the American College of Cardiology 1
Patients with muscle symptoms and CK 3-10x ULN should have their symptoms and CK levels followed weekly, with consideration of dose reduction or temporary discontinuation, as suggested by the American College of Cardiology 1
Patients with muscle symptoms and normal or mildly elevated CK should have their symptoms monitored, with consideration of dose reduction if symptoms are bothersome, according to the American College of Cardiology 1

Fibrates, particularly gemfibrozil, should be discontinued if used in combination with statins when CK is elevated, due to increased risk of statin-associated myopathy, as recommended by the American College of Cardiology 1
Niacin should be considered for discontinuation when used with statins if CK is elevated, as the combination increases myopathy risk, according to the American College of Cardiology 1
Immune checkpoint inhibitors should be held and corticosteroids initiated if CK elevation occurs during treatment, based on severity, as suggested by clinical guidelines 2

Advanced age, especially >80 years, with women at higher risk than men, is a risk factor for medication-induced CK elevation, according to the American College of Cardiology 1
Small body frame and frailty are risk factors for medication-induced CK elevation, as stated by the American College of Cardiology 1
Multisystem disease, such as chronic renal insufficiency, especially due to diabetes, is a risk factor for medication-induced CK elevation, according to the American College of Cardiology 1
Multiple medications (polypharmacy) is a risk factor for medication-induced CK elevation, as noted by the American College of Cardiology 1
Perioperative periods are a risk factor for medication-induced CK elevation, according to the American College of Cardiology 1
Hypothyroidism is a risk factor for medication-induced CK elevation, as stated by the American College of Cardiology 1

Baseline CK measurement should be obtained before initiating statin therapy, as recommended by the American College of Cardiology 1
CK should be measured if a patient reports muscle symptoms while on statins, according to the American College of Cardiology 1
Thyroid-stimulating hormone should be checked in patients with muscle symptoms, as hypothyroidism predisposes to myopathy, as suggested by the American College of Cardiology 1
Patients with moderate CK elevations (3-10x ULN) should be monitored more frequently with serial measurements, according to the American College of Cardiology 1
If statins are discontinued due to CK elevation, therapy should not be reinitiated until symptoms have resolved and CK levels have returned to normal, and then at a lower dose, as recommended by the American College of Cardiology 1

Not all muscle pain in statin users is due to the medication, and common causes such as exercise or strenuous work should be ruled out, as noted by the American College of Cardiology 1
Asymptomatic patients may have moderate CK elevations at baseline or during treatment, but can usually be treated with a statin with careful monitoring, according to the American College of Cardiology 1
Avoid restarting statins at the same dose after a myopathy episode; if reinitiation is necessary, use a lower dose or a different statin with lower myopathy risk, as recommended by the American College of Cardiology 1

For asymptomatic patients with CK <4x upper limit of normal (ULN), statins can generally be initiated or continued with careful monitoring, as recommended by the European Society of Cardiology 3, 4
For patients with CK ≥4x ULN, management depends on the presence of symptoms and the degree of elevation, with guidelines from the European Society of Cardiology suggesting a tailored approach 3, 4
Consider possible causes of transient CK elevation such as recent exercise before attributing elevation solely to medications, according to the European Heart Journal 4

For CK <4x ULN: Continue lipid-lowering therapy while monitoring CK, as recommended by the European Society of Cardiology 3
For CK 4-10x ULN without symptoms: Continue lipid-lowering therapy with more frequent monitoring, following guidelines from the European Society of Cardiology 3, 4
For CK >10x ULN: Stop statin treatment, check renal function, and monitor CK every 2 weeks, as advised by the European Society of Cardiology 3, 4

Consider alternate-day or once/twice weekly dosing regimens with efficacious statins like atorvastatin or rosuvastatin, as suggested by the European Heart Journal 4

Recheck CK levels 8-12 weeks after starting treatment or after dose adjustment, as recommended by the European Society of Cardiology 3
Once target lipid levels are achieved, monitor annually unless adherence problems or other specific reasons for more frequent reviews, following guidelines from the European Society of Cardiology 3

The combination of statins with gemfibrozil significantly increases myopathy risk and should be avoided, as warned by the American Diabetes Association 5